Creative Biolabs is a leading service provider that focuses on SARS-CoV-2 drug discovery services. Currently, various platforms have been established for screening SARS-CoV-2 in different populations, and we have successfully established a series of rRT-PCR assays for identifying SARS-CoV-2 and developed a series of IVD kits for our worldwide clients.
SARS-CoV-2, a member of the coronavirus family, is an enveloped RNA virus that has been identified in many countries, such as China, Japan, Singapore, and the United States. SARS-CoV-2 occurs mainly in humans and can cause a series of severe respiratory diseases. As a result, monitoring of the SARS-CoV-2 activity plays an important role in implementing suitable virus control measures. In particular, an effective detection system for screening SARS-CoV-2 in humans should be developed and widely used for in vitro diagnosis. Currently, a number of polymerase chain reaction (PCR)-based assays have been generated, including real-time reverse transcription PCR (rRT-PCR) and reverse transcription loop-mediated isothermal amplification (RT-LAMP), for rapid detection of SARS-CoV-2 infection in various samples. Recent studies have indicated that these assays are high-throughput, efficient, and powerful tools in practical detection. However, rRT-PCR and RT-LAMP methods have also shown several drawbacks, either an intricate instrument or a manpower consuming process for the detection of SARS-CoV-2 samples. In addition, it is widely accepted that the screening results should be evaluated by multiple assays. In this condition, a single-tube real-time RT-LAMP technology has been reported to offer a fast and high specificity PCR amplification and to complement those already available.
Fig.1 Comparative sensitivity of real-time RT-LAMP, one-step RT-PCR, and real-time RT-PCR methods. (Yu, 2015)
Recently, the efficient human-to-human transmission of SARS-CoV-2 has aroused much attention all over the world, especially in China. The WHO responded quickly by encouraging in vitro diagnostics development, coordinating SARS-CoV-2 detection for virus monitor, as well as supporting drug discovery in patients. Creative Biolabs has established a single-tube real-time RT-LAMP platform for the detection of SARS-CoV-2 virus RNA.
In general, amplification of SARS-CoV-2 can be achieved by using multiple reaction primer mixes at an optimized condition. The primer mixes are derived from the published data of SARS-CoV-2 genome sequences, and the primer design is based on different types of sequence alignment software. Creative Biolabs provides in vitro diagnostic kits development services of SARS-CoV-2 by using our unique real-time RT-LAMP platform. Our goal is to promote PCR-based detection kits to clinical diagnosis for SARS-CoV-2 screening in a wide variety of human populations. We have built a team of talented and motivated scientists and technicians to pursue our commitment.
As a reliable drug discovery company, Creative Biolabs is committed and proud to be part of this rewarding challenge by offering its support to the SARS-CoV-2 IVD kits development services and pre-clinical drug discovery for our clients. We are proud to partner with you on the journey of bringing novel candidate drugs to SARS-CoV-2 infection disease therapy in the clinic. If you are interested in our services, please contact us for more details.
|CAT||Product Name||Product Overview|
|VCok-Wyb031||SARS-CoV-2 S Gene Visual RT-LAMP Kit||This kit is based on the loop-mediated isothermal amplification (LAMP) technology and is specifically used to detect the S gene of a new coronavirus (SARS-CoV-2). This product is for research use only and is not intended for diagnostic use.|
|VCok-Wyb032||SARS-CoV-2 N Gene Visual RT-LAMP Kit||This kit is based on the loop-mediated isothermal amplification (LAMP) technology and is specifically used to detect the N gene of a new coronavirus (SARS-CoV-2). This product is for research use only and is not intended for diagnostic use.|
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.